A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329 on ClinicalTrials.gov · last registry update 2020-03-19

Finished June 2018, after enrolling 79 people. Primary outcome, as filed: Change From Baseline in HbA1c Levels.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Yale University
Sponsor type: Other
Enrollment: 79
Started: 2013-09
Primary completion: 2018-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in HbA1c Levels

Conditions studied

Type I Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.